This website is intended to provide the Group's stakeholders, including patients, healthcare professionals, local communities, and employees, with information about major sustainability initiatives implemented by the Group in fiscal 2024. Specific initiatives implemented in accordance with the Company's philosophy are presented in line with the environmental, social, and governance perspectives.

 

The Sustainability Report 2025 PDF version, which contains the same content as disclosed on this website, can be downloaded from the Sustainability Report archive page.

 

Explanations of medical and pharmaceutical terms appearing in this report have been provided to foster a wider understanding of the report's content.

Applied Guidelines

  • Global Reporting Initiative (GRI) Sustainability Reporting Standard
  • Environmental Reporting Guidelines, 2018 version, published by the Ministry of the Environment of Japan

Period covered

April 1, 2024, to March 31, 2025

(The report includes examples of activities from April 2025 and thereafter)

Issue timing

September 2025

(Previous report: September 2024; next report: September 2026)

Scope of reporting

Mitsubishi Tanabe Pharma and consolidated subsidiaries in Japan and overseas.

(The scope of reporting could differ in accordance with the examples being reported.)

Contact information

Contact Us